Search DIAN Data Resource Requests

Title:Evaluating the Role of Perivascular Spaces and White Matter Hyperintensities in Dominantly Inherited Alzheimer's Disease and their Relationship with Amyloid and Tau

Date of Request:07/19/2023

Status:pending approval

ID:DIAN-D2313

Aim 1:To assess the spatial distribution of v-PVS and WMH in mutation carriers vs. non-carriers

Aim 2:To assess the prevalence and severity of v-PVS and WMH in asymptomatic mutation carriers vs. non-carriers

Aim 3:To investigate the incidence of MRI-visible v-PVS and WMH in mutation carriers vs. non-carriers along the disease trajectory and their relationship with the incidence of amyloid and tau

Aim 4To investigate the spatial relationship between v-PVS/WMH and amyloid/tau accumulation using a disconnectomics approach

Title:Assessment of Basal Forebrain degeneration using MRI in Alzheimer's Disease

Date of Request:07/06/2023

Status:approved

ID:DIAN-D2312

Aim 1:To determine the pattern of basal forebrain measured by MRI degeneration in familial Alzheimer's disease and relationships with biomarkers

Aim 2:To compare the pattern of basal forebrain degeneration measured by MRI in familial Alzheimer's disease to sporadic disease

Title:Comparison of Astrocyte-related Markers in Down Syndrome and Autosomal-Dominant Alzheimer Disease Using the Amyloid- Tau-Neurodegeneration (AT(N)) Framework

Date of Request:06/30/2023

Status:approved

ID:DIAN-D2311

Aim 1:Evaluate and compare the association between plasma GFAP and imaging measures of AD in Down syndrome and ADAD.

Title:Modifiers of Alzheimer's disease: a genetic approach

Date of Request:04/28/2023

Status:pending

ID:DIAN-D2310

Aim 1:To identify genetic modifiers of disease presentation in PSEN1 mutation carriers

Title:Single-nucleus RNAseq of a humanized mouse model of Alzheimer's disease

Date of Request:04/24/2023

Status:pending approval

ID:DIAN- D2309

Aim 1:Generate a novel humanized mouse model of AD with disease variants in APP and APOE genes.

Aim 2:Perform deep behavioural and molecular phenotyping of the mouse model

Aim 3:Perform snRNAseq of multiple brain regions of mouse model and compare to human snRNAseq from patients with AD

Title:Evaluation of the neurovascular unit in the setting of pathogenesis and treatment of autosomal dominant Alzheimer disease

Date of Request:04/21/2023

Status:approved

ID:DIAN-D2308

Aim 1:Perform proteomic characterization of NVU disruption and develop imaging markers of vascular changes in ADAD.

Aim 2:Determine the trajectories of NVU disruption markers and their relation to the pattern of disease progression in ADAD.

Aim 3:Examine influence of NVU disruption on drug efficacy and safety outcome measures in ADAD.

Title:Biomarker progression modeling in autosomal-dominant Alzheimer’s disease and implications for clinical trial design

Date of Request:04/21/2023

Status:approved

ID:DIAN-D2307

Aim 1:Modeling biomarker progression in the DIAN population

Aim 2:Using biomarker progression modeling to inform clinical trial design

Title:Drug Dose Modeling for potential inclusion in the DIAN-TU 002 trial

Date of Request:04/04/2023

Status:approved

ID:DIAN-D2306

Aim 1:Conduct dose modeling projections for the patient population of interest in the study to determine dose selection and sample size.

Title:Biopsychosocial determinants of cognitive and biomarker trajectories in preclinical Alzheimer's disease

Date of Request:03/23/2023

Status:pending review

ID:DIAN-D2305

Aim 1:The first objective is to characterise the biopsychosocial determinants of AD across modifiable and non-modifiable factors throughout the lifespan across multiple cohorts including Memento, DIAN, WRAP, ADNI, BIOCARD, SMC amyloid, and other DPUK databases. The latent constructs, which have not previously been examined in such extensive detail, include physical health, mental health, diet, family history, sex, ethnicity, education, sociality, life functionality, employment, and traumatic brain injury.

Aim 2:The second objective is to explore an AD prediction model utilising PET amyloid data, building on objective 1. Designed utilising the significant constructs, the hypothesis is that this novel disease model will predict preclinical AD with relative accuracy in patient populations to facilitate earlier and more accurate disease diagnoses .

Aim 3:The third objective is to investigate the relationship between the biopsychosocial determinants included in the disease prediction model and structural brain changes (MRI). Utilising the BHC and healthy control cohorts, the study hypothesises that there will be a significant difference in health/lifestyle outcomes between the two populations as well as a significant relationship between these outcomes and level of cognitive/structural impairment, thus strengthening the role of biopsychosocial determinants in disease trajetory

Title:Temporal ordering of plasma biomarkers and their association with amyloid pathology, cerebral atrophy, cerebral metabolism and cognition in autosomal dominant Alzheimer’s disease

Date of Request:03/08/2023

Status:withdrawn

ID:DIAN-D2304

Aim 1:Investigate the temporal order of AD-related plasma biomarker (abeta42/40 ratio, p-tau181, GFAP and NFL) divergence between ADAD mutation carriers and non-carriers as a function of EYO.

Aim 2:Investigate the association of AD-related plasma biomarkers with Aβ pathology (PiB-PET) and ADAD severity (CDR global) in mutation carriers.

Aim 3:Investigate the cross-sectional association of plasma biomarkers with neurodegeneration (hippocampal volume and precuneus thickness), cognition (MMSE, CDR-SB and composite cognition score) and cerebral metabolism (FDG-PET).

Aim 4Association of plasma biomarkers with subsequent neurodegeneration, cognitive decline, cerebral hypometabolism.